Premium
P2‐015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials
Author(s) -
Hill Derek L.,
Novak Gerald P.,
Wolz Robin,
Liu Enchi,
Lucas Prisca,
Fox Nick C.,
Scheltens Philip,
Gray Katherine R.,
Booth Kevin,
Einstein Steven G.,
Schmidt Mark E.,
Li David Jianjun,
Styren Scot D.,
Margolin Richard A.,
McCarthy Timothy J.,
Brashear Robert Robert
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1219
Subject(s) - precuneus , standardized uptake value , medicine , nuclear medicine , psychology , positron emission tomography , psychiatry , cognition
mL (n1⁄4516), 5.86 (1.10) mL (n1⁄4518) and 50.56 (22.89) mL (n1⁄4517), respectively. The left hippocampus volume (LHV) was 0.117 mL (95% CI: 0.088-0.145) smaller than the right hippocampus volume (RHV) with volumes of 2.87 (0.56) mL (n1⁄4518) and 2.99 (0.59) mL (n1⁄4518), respectively. Mild AD subjects (MMSE 21) had a larger brain volume (95% CI: 16.392-51.390) and LHV (95% CI: 0.012-0.206) than moderate AD patients (MMSE 20). In contrast significant differences were not observed between mild and moderate AD subjects in the RHVand total hippocampus volume or ventricular volume. Whole brain and ventricles volume were not impacted by APOE4 status of subjects whereas a difference was found for LHV (95% CI:0.074-0.278), RHV (95% CI:0.064-0.283) and total (95% CI:0.148-0.553) hippocampus volume with APOE4-carriers presenting with more atrophied structures. Conclusions: These data from a partial sample of EPOCH trial participants showed differences in whole brain atrophy stage between mild and moderate AD patients and a higher hippocampal atrophy in APOE4-carriers They also suggest that the left hippocampus is more vulnerable to atrophy than the right hippocampus. A comparison of our study brain parameters to ADNI data will also be presented.